122 related articles for article (PubMed ID: 12654752)
1. A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals.
Ferguson NM; Mallett S; Jackson H; Roberts N; Ward P
J Antimicrob Chemother; 2003 Apr; 51(4):977-90. PubMed ID: 12654752
[TBL] [Abstract][Full Text] [Related]
2. Emergence of drug-resistant influenza virus: population dynamical considerations.
Regoes RR; Bonhoeffer S
Science; 2006 Apr; 312(5772):389-91. PubMed ID: 16627735
[TBL] [Abstract][Full Text] [Related]
3. Antivirals and the control of influenza outbreaks.
Hota S; McGeer A
Clin Infect Dis; 2007 Nov; 45(10):1362-8. PubMed ID: 17968836
[TBL] [Abstract][Full Text] [Related]
4. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
[TBL] [Abstract][Full Text] [Related]
5. Emergence and transmission of amantadine-resistant influenza A in a nursing home.
Schilling M; Gravenstein S; Drinka P; Cox N; Krause P; Povinelli L; Shult P
J Am Geriatr Soc; 2004 Dec; 52(12):2069-73. PubMed ID: 15571544
[TBL] [Abstract][Full Text] [Related]
6. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies.
Lackenby A; Democratis J; Siqueira MM; Zambon MC
Antivir Ther; 2008; 13(6):809-20. PubMed ID: 18839782
[TBL] [Abstract][Full Text] [Related]
7. Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007.
Tashiro M; McKimm-Breschkin JL; Saito T; Klimov A; Macken C; Zambon M; Hayden FG;
Antivir Ther; 2009; 14(6):751-61. PubMed ID: 19812437
[TBL] [Abstract][Full Text] [Related]
8. Influenza virus susceptibility and resistance to oseltamivir.
Aoki FY; Boivin G; Roberts N
Antivir Ther; 2007; 12(4 Pt B):603-16. PubMed ID: 17944268
[TBL] [Abstract][Full Text] [Related]
9. Antivirals and influenza: frequency of resistance.
Monto AS
Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S110-2. PubMed ID: 18820569
[TBL] [Abstract][Full Text] [Related]
10. Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases.
Nijhuis M; van Maarseveen NM; Boucher CA
Handb Exp Pharmacol; 2009; (189):299-320. PubMed ID: 19048205
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of antiviral-resistant influenza viruses in the Netherlands, 2005-2008.
Jonges M; van der Lubben IM; Dijkstra F; Verhoef L; Koopmans M; Meijer A
Antiviral Res; 2009 Sep; 83(3):290-7. PubMed ID: 19591877
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.
LaForce C; Man CY; Henderson FW; McElhaney JE; Hampel FC; Bettis R; Kudule L; Harris J; Yates P; Tisdale M; Webster A
Clin Ther; 2007 Aug; 29(8):1579-90; discussion 1577-8. PubMed ID: 17919541
[TBL] [Abstract][Full Text] [Related]
13. Transmission dynamics of an influenza model with vaccination and antiviral treatment.
Qiu Z; Feng Z
Bull Math Biol; 2010 Jan; 72(1):1-33. PubMed ID: 19568726
[TBL] [Abstract][Full Text] [Related]
14. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses.
Gooskens J; Jonges M; Claas EC; Meijer A; Kroes AC
J Infect Dis; 2009 May; 199(10):1435-41. PubMed ID: 19392620
[TBL] [Abstract][Full Text] [Related]
15. Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy.
Ludwig S
J Antimicrob Chemother; 2009 Jul; 64(1):1-4. PubMed ID: 19420020
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of amantadine-resistance influenza a (H3N2) in six prefectures, Japan, in the 2005-2006 season.
Saito R; Li D; Suzuki Y; Sato I; Masaki H; Nishimura H; Kawashima T; Shirahige Y; Shimomura C; Asoh N; Degawa S; Ishikawa H; Sato M; Shobugawa Y; Suzuki H
J Med Virol; 2007 Oct; 79(10):1569-76. PubMed ID: 17705168
[TBL] [Abstract][Full Text] [Related]
17. Anti-influenza drugs: the development of sialidase inhibitors.
von Itzstein M; Thomson R
Handb Exp Pharmacol; 2009; (189):111-54. PubMed ID: 19048199
[TBL] [Abstract][Full Text] [Related]
18. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.
Herlocher ML; Truscon R; Elias S; Yen HL; Roberts NA; Ohmit SE; Monto AS
J Infect Dis; 2004 Nov; 190(9):1627-30. PubMed ID: 15478068
[TBL] [Abstract][Full Text] [Related]
19. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance.
Ferraris O; Lina B
J Clin Virol; 2008 Jan; 41(1):13-9. PubMed ID: 18055254
[TBL] [Abstract][Full Text] [Related]
20. Genetic microheterogeneity of emerging H275Y influenza virus A (H1N1) in Toronto, Ontario, Canada from the 2007-2008 respiratory season.
Eshaghi A; Bolotin S; Burton L; Low DE; Mazzulli T; Drews SJ
J Clin Virol; 2009 Jun; 45(2):142-5. PubMed ID: 19451021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
